Researchers are rapidly studying the SARS-COV-2 genome to look for clues that can stop the progression of the virus. ACE2 is one of the suspected cell receptors via which the virus invades a host cell. Understanding this process is key for diagnostics and treatment.

The CRG has previously developed tools, like FoldX, to test protein-protein interactions and find new treatments for various diseases. It is being used by scientists to test how ACE2 interacts with proteins on surface of the new coronavirus.
 
The tools we have invested in years ago is now playing its part in slowing the progression of a rapidly emerging disease. Researchers and non-profit organisations can use FoldX for free, and the CRG has extended the free license for businesses for a thirty day period.